Intellia Secures $400M Non-Dilutive Debt Facility with OrbiMed
The company secured a $400 million facility for HAE drug lonvo-z and pipeline programs, enhancing financial flexibility without shareholder dilution.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day